JP2008516610A - 酵母を用いた慢性ｃ型肝炎感染の治療 - Google Patents

酵母を用いた慢性ｃ型肝炎感染の治療 Download PDF

Info

Publication number
JP2008516610A
JP2008516610A JP2007537026A JP2007537026A JP2008516610A JP 2008516610 A JP2008516610 A JP 2008516610A JP 2007537026 A JP2007537026 A JP 2007537026A JP 2007537026 A JP2007537026 A JP 2007537026A JP 2008516610 A JP2008516610 A JP 2008516610A
Authority
JP
Japan
Prior art keywords
hcv
vaccine
protein
seq
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007537026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516610A5 (enExample
Inventor
デューク，リチャード，シー．
フランツソフ，アレックス
ハラー，アウレリア
キング，トーマス，エイチ．
Original Assignee
グローブイミューン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローブイミューン，インコーポレイテッド filed Critical グローブイミューン，インコーポレイテッド
Publication of JP2008516610A publication Critical patent/JP2008516610A/ja
Publication of JP2008516610A5 publication Critical patent/JP2008516610A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007537026A 2004-10-18 2005-10-18 酵母を用いた慢性ｃ型肝炎感染の治療 Pending JP2008516610A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62015804P 2004-10-18 2004-10-18
PCT/US2005/037499 WO2006044923A2 (en) 2004-10-18 2005-10-18 Yeast-based therapeutic for chronic hepatitis c infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011216827A Division JP2012034700A (ja) 2004-10-18 2011-09-30 酵母を用いた慢性ｃ型肝炎感染の治療用ワクチンおよびその使用方法

Publications (2)

Publication Number Publication Date
JP2008516610A true JP2008516610A (ja) 2008-05-22
JP2008516610A5 JP2008516610A5 (enExample) 2008-12-04

Family

ID=36203669

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007537026A Pending JP2008516610A (ja) 2004-10-18 2005-10-18 酵母を用いた慢性ｃ型肝炎感染の治療
JP2011216827A Pending JP2012034700A (ja) 2004-10-18 2011-09-30 酵母を用いた慢性ｃ型肝炎感染の治療用ワクチンおよびその使用方法
JP2013162490A Withdrawn JP2014012679A (ja) 2004-10-18 2013-08-05 酵母を用いた慢性ｃ型肝炎感染の治療用ワクチンおよびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011216827A Pending JP2012034700A (ja) 2004-10-18 2011-09-30 酵母を用いた慢性ｃ型肝炎感染の治療用ワクチンおよびその使用方法
JP2013162490A Withdrawn JP2014012679A (ja) 2004-10-18 2013-08-05 酵母を用いた慢性ｃ型肝炎感染の治療用ワクチンおよびその使用方法

Country Status (12)

Country Link
US (5) US7632511B2 (enExample)
EP (2) EP1809773B1 (enExample)
JP (3) JP2008516610A (enExample)
KR (1) KR20070068460A (enExample)
CN (2) CN102614510A (enExample)
AU (1) AU2005295317B2 (enExample)
BR (1) BRPI0516356A (enExample)
CA (1) CA2584562A1 (enExample)
IL (1) IL182609A (enExample)
MX (1) MX2007004662A (enExample)
SG (1) SG156652A1 (enExample)
WO (1) WO2006044923A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504623A (ja) * 2009-09-14 2013-02-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 酵母ベースの免疫療法生成物及び応答の調節
JP2014523878A (ja) * 2011-06-14 2014-09-18 グローブイミューン，インコーポレイテッド Ｄ型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
AU2003301021C1 (en) * 2002-12-16 2010-02-18 Globelmmune, Inc. Yeast-based vaccines as immunotherapy
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
US20090186047A1 (en) * 2006-04-25 2009-07-23 Intercell Ag HCV Vaccinations
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
NZ720288A (en) * 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US7840668B1 (en) * 2007-05-24 2010-11-23 Avaya Inc. Method and apparatus for managing communication between participants in a virtual environment
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
US9089508B2 (en) * 2007-10-09 2015-07-28 The University Of Melbourne Method of transfection and compositions therefor
US8728489B2 (en) * 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
CN102282265B (zh) * 2008-11-28 2020-07-24 埃默里大学 用于治疗传染病和肿瘤的方法
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
JP2013522302A (ja) * 2010-03-14 2013-06-13 グローブイミューン，インコーポレイテッド 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
EP2651439B1 (en) * 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AP2013007110A0 (en) 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
EP2849779B1 (en) * 2012-05-16 2021-01-06 Adelaide Research & Innovation Pty Ltd. Cellular vaccine and method of inducing an immune response in a subject
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
US9925259B2 (en) 2013-02-19 2018-03-27 National University Corporation Kobe University Immunogenic polypeptide surface layer-expressing bifidobacterium
DK3292873T3 (da) 2013-02-22 2019-06-03 Curevac Ag Kombination af vaccination og hæmning af PD-1-vejen
US9974845B2 (en) 2013-02-22 2018-05-22 Curevac Ag Combination of vaccination and inhibition of the PD-1 pathway
WO2014160747A2 (en) 2013-03-26 2014-10-02 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
KR102409372B1 (ko) * 2014-04-11 2022-06-16 글로브이뮨 효모 면역 요법 및 타입 i 인터페론 감도
EP3256140B1 (en) 2015-01-09 2020-04-01 Etubics Corporation Compositions for ebola virus vaccination
JP6647315B2 (ja) 2015-01-09 2020-02-14 イーチュービクス コーポレイション 組み合わせ免疫療法のための方法および組成物
EP3286213B1 (en) 2015-04-20 2021-08-04 Etubics Corporation Methods and compositions for combination immunotherapy
GB201520638D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2018055535A2 (en) 2016-09-21 2018-03-29 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
BR112020012360A2 (pt) 2017-12-21 2020-11-24 Ena Therapeutics Pty Ltd compostos otimizados
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
WO2020257870A1 (en) 2019-06-26 2020-12-30 Ena Therapeutics Pty Ltd Novel molecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide
WO2004005473A2 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains
WO2004046176A1 (en) * 2002-11-15 2004-06-03 Glaxo Group Limited Vaccine against hcv
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5523215A (en) * 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US6194140B1 (en) 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
PL169273B1 (pl) * 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
EP0468657A3 (en) 1990-07-09 1992-02-05 Tonen Corporation Non-a non b hepatitis-specific antigen and its use in hepatitus diagnosis
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US6190864B1 (en) 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
WO1992022571A1 (en) 1991-06-13 1992-12-23 Baxter Diagnostics Inc. Immunoassay for non-a non-b hepatitis
GB9203803D0 (en) 1992-02-21 1992-04-08 Wellcome Found A recombinant polypeptide
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
ES2239819T3 (es) * 1993-11-04 2005-10-01 Innogenetics N.V. Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c.
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
PT773957E (pt) * 1994-07-29 2005-11-30 Chiron Corp Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos
PT1510580E (pt) * 1994-07-29 2009-02-18 Novartis Vaccines & Diagnostic Polipéptido e2 truncado da hepatite c e métodos para a sua obtenção
SG71728A1 (en) * 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
GB9416671D0 (en) * 1994-08-17 1994-10-12 Biocine Spa Assay
GB9422814D0 (en) * 1994-11-11 1995-01-04 Medinnova Sf Chemical method
KR100195833B1 (ko) 1995-12-07 1999-06-15 윤종용 팩시밀리에서 자체진단 구현방법
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
ATE389712T1 (de) * 1997-01-31 2008-04-15 Edward P Cohen Krebs immuntherapie mit semi-allogenen zellen
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
FR2760367B1 (fr) 1997-03-06 1999-04-30 Pasteur Merieux Serums Vacc Composition vaccinale destinee a la prevention ou au traitement des hepatites c
ATE437951T1 (de) 1997-05-06 2009-08-15 Novartis Vaccines & Diagnostic Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US20050037018A1 (en) 2003-06-20 2005-02-17 Innogentics N.V. HCV combination therapy
US7052696B2 (en) 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6747135B1 (en) 1998-10-16 2004-06-08 The Board Of Trustees For The Leland Stanford Junior University Fluorescent dye binding peptides
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
US20050074465A1 (en) * 1999-11-24 2005-04-07 Michael Houghton HCV fusion proteins with modified NS3 domains
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ES2260078T3 (es) 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
PE20020908A1 (es) * 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
AR035867A1 (es) * 2001-04-24 2004-07-21 Innogenetics Nv Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e
US20040126395A1 (en) 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2003051912A2 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
BR0314166B8 (pt) * 2002-09-09 2021-07-27 Chiron Corp teste de hcv
US20040138204A1 (en) * 2002-10-30 2004-07-15 Harrington James Frederick Compositions and methods for pain reduction
WO2004041853A2 (en) * 2002-11-08 2004-05-21 Innogenetics N.V. Hcv vaccine compositions comprising e1 and ns3 peptides
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US6989892B2 (en) * 2004-03-22 2006-01-24 Fluke Corporation Optical fiber propagation time measurement
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20080182895A1 (en) 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
JP5570819B2 (ja) 2007-02-02 2014-08-13 グローブイミューン，インコーポレイテッド 酵母を含む組成物および酵母を増殖させる方法
EP2134358A1 (en) 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US8728489B2 (en) * 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide
WO2004005473A2 (en) * 2002-07-02 2004-01-15 Chiron Corporation Hcv fusion proteins with modified ns3 domains
WO2004046176A1 (en) * 2002-11-15 2004-06-03 Glaxo Group Limited Vaccine against hcv
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6011028270; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．　７１，　Ｍｏ．　８, 1997, ｐ．　６０１１-６０１９ *
JPN6011028272; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．　７０，　Ｎｏ．　１, 1996, ｐ．　２３２-２４０ *
JPN6012065782; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．　６８，　Ｎｏ．　５, 1994, ｐ．　３３３４-３３４２
JPN6012065784; Ｊ．　Ｉｎｆｅｃｔ．　Ｄｉｓ． Ｖｏｌ．　１８５, 2002, ｐ．　７２０-７２７

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504623A (ja) * 2009-09-14 2013-02-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 酵母ベースの免疫療法生成物及び応答の調節
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
JP2014523878A (ja) * 2011-06-14 2014-09-18 グローブイミューン，インコーポレイテッド Ｄ型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法

Also Published As

Publication number Publication date
US20090074805A1 (en) 2009-03-19
EP1809773A4 (en) 2009-12-23
US8821892B2 (en) 2014-09-02
IL182609A (en) 2014-04-30
US7625569B2 (en) 2009-12-01
KR20070068460A (ko) 2007-06-29
CN102614510A (zh) 2012-08-01
US20100150963A1 (en) 2010-06-17
WO2006044923A2 (en) 2006-04-27
JP2012034700A (ja) 2012-02-23
CN101437964A (zh) 2009-05-20
US7632511B2 (en) 2009-12-15
US8388980B2 (en) 2013-03-05
CA2584562A1 (en) 2006-04-27
BRPI0516356A (pt) 2008-09-02
HK1110358A1 (en) 2008-07-11
EP2460533A3 (en) 2014-01-08
US8007816B2 (en) 2011-08-30
SG156652A1 (en) 2009-11-26
US20130309265A1 (en) 2013-11-21
AU2005295317B2 (en) 2011-10-13
EP2460533A2 (en) 2012-06-06
JP2014012679A (ja) 2014-01-23
US20080107671A1 (en) 2008-05-08
CN101437964B (zh) 2012-06-13
IL182609A0 (en) 2007-07-24
EP1809773A2 (en) 2007-07-25
AU2005295317A1 (en) 2006-04-27
EP1809773B1 (en) 2014-07-16
MX2007004662A (es) 2007-11-23
US20080069831A1 (en) 2008-03-20
WO2006044923A3 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
EP1809773B1 (en) Yeast-based therapeutic for chronic hepatitis c infection
US7439042B2 (en) Yeast-based therapeutic for chronic hepatitis C infection
US8728489B2 (en) Immunotherapy for chronic hepatitis C virus infection
KR101492524B1 (ko) 면역 반응 유도를 위한 효모-기반 백신
CN103732250A (zh) 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
AU2009273949A1 (en) Compositions and methods for the treatment of hepatitis C
AU2011254055B2 (en) Yeast-based therapeutic for chronic hepatitis C infection
HK1110358B (en) Yeast-based therapeutic for chronic hepatitis c infection
HK1171197A (en) Yeast-based therapeutic for chronic hepatitis c infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081017

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110601

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121003

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121015

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20121214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140709